
A close-up of hands holding a tablet and a pen

Description automatically generated**U.S. Non-opioid Pain Patches Market**

According to Intelli, the U.S. Non-opioid Pain Patches Market size was valued at USD 317.8 Million in 2024 and is projected to reach USD 464.71 Million by 2032, growing at a CAGR of 5.39% from 2025 to 2032.



Non-opioid pain patches represent a groundbreaking advancement in pain management, offering effective relief without the risks associated with opioid-based treatments. These transdermal patches work by delivering non-addictive analgesics, such as lidocaine, capsaicin, or NSAIDs, through the skin and into the bloodstream or local tissue, allowing for a controlled and sustained release of medication directly at or near the site of pain. This targeted delivery system bypasses the digestive system and avoids the peaks and troughs of oral medications, resulting in more stable pain control with fewer gastrointestinal side effects. Moreover, because the active ingredients are non-opioid and locally administered, the risk of developing tolerance, addiction, or systemic complications is significantly reduced. Non-opioid patches are emerging as a transformative option for managing chronic conditions like arthritis, musculoskeletal pain, and neuropathy. As the demand for safer, more sustainable alternatives to opioids continues to rise, these patches stand out as a promising solution in the ongoing fight against the opioid crisis.

**U.S. Non-opioid Pain Patches Market Definition**

**​**The U.S. non-opioid pain patches market is a specialized segment within the broader pain management industry, focusing on transdermal patches that deliver analgesics without the use of opioids. These patches, which commonly contain ingredients like lidocaine, diclofenac, capsaicin, and methyl salicylate, are designed to treat chronic pain conditions. As awareness of the opioid crisis intensifies, and demand for safer pain management alternatives increases, the U.S. market for non-opioid pain patches has seen substantial growth. This market signifies a pivotal transition in healthcare toward more innovative, safer, and patient-focused approaches to managing chronic pain.

**U.S. Non-opioid Pain Patches Market Overview**

​The U.S. non-opioid pain patches market is experiencing significant growth, driven by a confluence of factors that address the urgent need for safer, more effective pain A close-up of hands holding a tablet and a pen

Description automatically generatedmanagement solutions. One of the key drivers fueling the market is the rising incidence of chronic pain conditions like arthritis, neuropathy, and musculoskeletal disorders, which impact millions of Americans and highlight the urgent need for safer, non-opioid alternatives to conventional pain treatments. In addition, technological advancements in transdermal drug delivery systems have significantly improved how non-opioid pain patches work, both in terms of effectiveness and ease of use. Modern patches now offer controlled, sustained release of medication, ensuring a consistent therapeutic effect over time without the peaks and troughs common with oral drugs. Innovations such as enhanced skin permeability, improved adhesive materials, and smart delivery mechanisms allow for better absorption of active ingredients, even through the skin's protective barrier. Moreover, increased awareness of the dangers linked to opioid use, such as addiction and overdose combined with strict regulatory initiatives favoring non-opioid alternatives, has accelerated the adoption of non-opioid pain patches as a safer, more responsible option for pain management. The aging U.S. population, which is more susceptible to chronic pain, further amplifies demand. Collectively, these factors underscore a paradigm shift in pain management, positioning non-opioid pain patches as a pivotal component in addressing the nation's pain relief needs.​

**U.S. Non-opioid Pain Patches Market Segmentation**

​The U.S. non-opioid pain patches market is segmented based on patch type, therapeutic application, and distribution channel, each contributing to the market's growth and diversification.

**U.S. Non-opioid Pain Patches Market, By Patch Type**

* **Lidocaine Patches**
* **Diclofenac Patches**
* **Capsaicin Patches**
* **Methyl Salicylate and Ketoprofen Patches**

In this Segment, Lidocaine Patches commanding the largest market share. These patches are preferred for their demonstrated effectiveness in delivering targeted pain relief for conditions like neuropathy and musculoskeletal disorders, while minimizing the risk of systemic side effects. Capsaicin patches, recognized for their ability to reduce substance A close-up of hands holding a tablet and a pen

Description automatically generatedP, a neurotransmitter that plays a key role in pain signaling, are expected to see the fastest growth. This growth is fueled by growing concerns about the risks of opioids and a broader shift toward non-invasive, safer pain management alternatives. Diclofenac and methyl salicylate patches also contribute to the market, offering targeted relief for inflammatory and musculoskeletal conditions. This segmentation underscores the diverse applications and growing adoption of non-opioid pain patches in the U.S., reflecting a broader trend towards safer, more effective pain management alternatives.​

**U.S. Non-opioid Pain Patches Market, By Therapeutic Applications**

* **Chronic Pain Relief**
* **Acute Pain Relief**
* **Musculoskeletal Pain Relief**
* **Postoperative Pain Management**

The U.S. non-opioid pain patches market is diverse in its therapeutic applications, addressing a range of pain management needs. Chronic pain relief is a major segment, as these patches are increasingly used to manage long-term conditions like arthritis, neuropathy, and back pain. Additionally, acute pain relief is another key application, offering effective treatment for injuries or sudden onset pain. Musculoskeletal pain relief is a prominent area, where these patches target inflammation and discomfort in muscles, and bones. Postoperative pain management also contributes to market growth, as non-opioid patches help reduce pain after surgeries, allowing patients to recover with fewer side effects and a lower risk of dependency.

**U.S. Non-opioid Pain Patches Market, By Distribution Channels**

* **Retail Pharmacies**
* **Online Pharmacies**
* **Hospital Pharmacies**

The distribution channels for non-opioid pain patches in the U.S. market are diverse, catering to different consumer preferences and accessibility needs. Retail pharmacies hold the largest share, as they provide easy access to both over-the-counter and prescription pain relief products, making them a primary choice for consumers seeking convenience. Online pharmacies are experiencing rapid growth, driven by the increasing demand for home delivery and the ability to shop from the comfort of one's home, a trend A close-up of hands holding a tablet and a pen

Description automatically generatedaccelerated by the rise of e-commerce. Hospital pharmacies are also a key player in the market, especially for prescribing non-opioid pain patches in postoperative care and chronic pain management, where medical oversight and expert advice are crucial. This multi-channel distribution strategy ensures that non-opioid pain patches are widely accessible, reaching a diverse patient base and enhancing overall market reach.

**Key Players**

The “U.S. Non-opioid Pain Patches Market" study report will provide valuable insight emphasizing the U.S. market. The major players in the market Acorda Therapeutics, Inc., Teva Pharmaceutical Industries Ltd., GSK plc, Teikoku Pharma, Mylan N.V., Pfizer Inc., Johnson & Johnson, AbbVie Inc., Horizon Therapeutics plc, Alkermes, Endo, Inc., Hisamitsu Pharmaceutical Co., Inc., Novartis AG, Amgen Inc., Astellas Pharma Inc. among others. Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

**Key Development**

* In 2024, Hisamitsu Pharmaceuticals began clinical development in the U.S for HP-3150. It is a transdermal patch consisting diclofenac sodium, and is used for chronic lower back pain.

**Market Attractiveness**

The image of market attractiveness provided further helps to get information about the region leading in the U.S. Non-opioid Pain Patches Market. We cover the major impacting factors driving the industry growth in the given region.

**Porter’s Five Forces**

The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be used to assess the competitive landscape U.S. Non-opioid Pain Patches Market, gauge the attractiveness of a particular sector, and assess investment possibilities.

A close-up of hands holding a tablet and a pen

Description automatically generatedTABLE OF CONTENT

1 **INTRODUCTION OF U.S. NON-OPIOID PAIN PATCHES MARKET**

* 1. Overview of the market
  2. Scope of report
  3. Assumptions

1. **EXECUTIVE SUMMARY**
2. **RESEARCH METHODOLOGY**
   1. Data Mining
   2. Validation
   3. Primary Interviews
   4. List of Data sources
3. **U.S. NON-OPIOID PAIN PATCHES MARKET OUTLOOK**
   1. Overview
   2. Market Dynamics
      1. Drivers
      2. Restrains
      3. Opportunities
      4. Trends
   3. Portes Five FORCE Model
   4. Value Chain Analysis

**5 U.S. NON-OPIOID PAIN PATCHES MARKET, BY PATCH TYPE**

5.1 Overview

A close-up of hands holding a tablet and a pen

Description automatically generated5.2 Lidocaine Patches

5.3 Diclofenac Patches

5.4 Capsaicin Patches

5.5 Methyl Salicylate and Ketoprofen Patches

**6 U.S. NON-OPIOID PAIN PATCHES MARKET, BY** **THERAPEUTIC APPLICATIONS**

6.1 Overview

6.2 Chronic Pain Relief

6.3 Acute Pain Relief

6.4 Musculoskeletal Pain Relief

6.5 Postoperative Pain Management

**7 U.S. NON-OPIOID PAIN PATCHES MARKET, BY DISTRIBUTION CHANNELS**

7.1 Overview

7.2 Retail Pharmacies

7.3 Online Pharmacies

7.4 Hospital Pharmacies

1. **U.S. NON-OPIOID PAIN PATCHES MARKET COMPETITIVE LANDSCAPE**
   1. Overview
   2. Company Market Ranking
   3. Key Developments Strategies
2. A close-up of hands holding a tablet and a pen

   Description automatically generated**COMPANY PROFILES**

**9.1 Acorda Therapeutics, Inc.**

* + 1. Overview
    2. Financial Performance
    3. roduct Outlook
    4. Key developments
  1. **Teva Pharmaceutical Industries Ltd.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  2. **GSK**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  3. **Teikoku Pharma**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  4. **Mylan N.V.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. A close-up of hands holding a tablet and a pen

        Description automatically generatedKey developments
  5. **Pfizer Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  6. **Johnson & Johnson**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  7. **AbbVie Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments

* 1. **Horizon Therapeutics plc**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  2. **Alkermes**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. A close-up of hands holding a tablet and a pen

        Description automatically generatedKey developments
  3. **Endo, Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  4. **Hisamitsu Pharmaceutical Co., Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  5. **Novartis AG**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  6. **Amgen Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  7. **Astellas Pharma Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments

1. A close-up of hands holding a tablet and a pen

   Description automatically generated**KEY DEVELOPMENTS**
   1. Product Launches/Developments
   2. Merges and Acquisitions
   3. Business Expansions
   4. Partnerships and Collaborations
2. **Appendix**

11.1 Related Research